Rakovina Therapeutics Announces $1.5 Million Private Placement

Article content

VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million.

Article content

Pursuant to the Offering, Rakovina will issue up to 15 million equity units (“Units”) at an offering price of $0.10 per Unit, with each Unit consisting of one common share and one-half of one common share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to acquire one additional common share at an exercise price of $0.20 exercisable for a period of 24 months from issuance.

Article content

Article content

Article content

Proceeds from the Offering will be used to advance Rakovina’s pipeline, with a primary focus on in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through the Company’s collaboration with Variational AI. Funds will also support advancement of the kt-3000 LNP formulation program through in vitro and in vivo characterization, ongoing kt-2000AI compound development, and the continued expansion of the Company’s AI-enabled drug discovery collaborations. Remaining proceeds will be used for general working capital purposes.

Article content

Article content

The Units will be sold on a non-brokered “private placement” basis in accordance with applicable Canadian securities laws and under applicable exemptions from prospectus and registration requirements and the securities will be subject to resale restrictions for a period of four months plus one day from the date of issue.

Article content

About Rakovina Therapeutics Inc.

Article content

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

Article content

Article content

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Article content

Article content

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Article content

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

Article content

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.